Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.73 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.52 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137272 | 0.85 | AR (0.74) | AR | |
| SCHEMBL4137264 | 0.85 | AR (0.74) | AR | |
| SCHEMBL14252941 | 0.85 | AR (0.74) | AR | |
| SCHEMBL8407112 | 0.85 | KDR (0.69) | ARKDRCNR2PDK1LMNA | |
| SCHEMBL20646267 | 0.84 | AR (1.00) | AR | |
| SCHEMBL20326887 | 0.84 | AR (1.00) | AR | |
| SCHEMBL13520476 | 0.84 | AR (0.57) | ARCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1291336 | 0.83 | KDR (0.71) | KDRCNR2PDK1LMNAKCNJ5 | |
| SCHEMBL29625148 | 0.83 | KDR (0.71) | KDRCNR2PDK1LMNAKCNJ5 | |
| SCHEMBL29625146 | 0.83 | KDR (0.71) | KDRCNR2PDK1LMNAKCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305636-A1 | Selective androgen receptor modulators and methods of use thereof | University of Tennessee Research Foundation (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7919647-B2 | N-(3-substituted-4-cyano)phenyl-2-hydroxy-2-methyl-3-(4-cyano)phenoxy propamides; spermatogenesis inhibitors, hormone replacement therapy, anticarcinogenic, antiproliferative agents for prostate cancer, apoptotic agents; bone and muscle disorders | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-7645898-B2 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-01-12 | — | — | US | disclosed |
| US-7595402-B2 | Prodrugs of selective androgen receptor modulators and methods of use thereof | GTX, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20070173546-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-26 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173546-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | AR 1/4885KDR 1320/4885CNR2 561/4885 |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | AR 1/4885KDR 1320/4885CNR2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.